TAK-147 (Takeda).
TAK-147 is a CNS-specific acetylcholinesterase inhibitor under development by Takeda as a potential treatment for Alzheimer's disease. By November 1999, it had entered phase III trials in Japan [348496]. In August 1999, Lehman Brothers predicted product launch in 2002, with potential peak sales of $250 million in 2012 [349228].
Mucke
H
H
HM Pharma Consultancy, Wien, Austria. h.mucke@hmpharmacon.com
D000544:Alzheimer Disease / Q000188:drug therapy / Q000201:enzymology; D000818:Animals; D001552:Benzazepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans
D001552:Benzazepines; D002800:Cholinesterase Inhibitors; C099872:TAK 147